<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "4: generally", fill: "#ccf"},
{source: "4: generally", target: "4: manufacturing", fill: "#ccf"},
{source: "4: manufacturing", target: "4: participate", fill: "#ccf"},
{source: "4: participate", target: "4: development", fill: "#ccf"},
{source: "4: development", target: "4: commercialization activities", fill: "#ccf"},
{source: "4: generally", target: "5: product development activities", fill: "#faebd7"},
{source: "5: product development activities", target: "5: commercializing", fill: "#faebd7"},
{source: "5: product development activities", target: "6: clinical trials", fill: "#560319"},
{source: "6: clinical trials", target: "6: candidates could severely harm", fill: "#560319"},
{source: "6: clinical trials", target: "7: successful commercialization", fill: "#138808"},
{source: "7: successful commercialization", target: "7: product candidates", fill: "#138808"},
{source: "7: product candidates", target: "7: regulatory approval", fill: "#138808"},
{source: "7: regulatory approval", target: "7: each market", fill: "#138808"},
{source: "7: each market", target: "7: collaborators", fill: "#138808"},
{source: "7: successful commercialization", target: "8: candidates", fill: "#50c878"},
{source: "8: candidates", target: "8: regulatory", fill: "#50c878"},
{source: "8: candidates", target: "19: addition clinical trials", fill: "#f0ffff"},
{source: "19: addition clinical trials", target: "19: potential products often", fill: "#f0ffff"},
{source: "19: potential products often", target: "19: continue development efforts", fill: "#f0ffff"},
{source: "19: continue development efforts", target: "19: candidates", fill: "#f0ffff"},
{source: "19: addition clinical trials", target: "24: potential products", fill: "#0047ab"},
{source: "24: potential products", target: "24: marketed abroad", fill: "#0047ab"},
{source: "24: marketed abroad", target: "24: regulation by foreign governments", fill: "#0047ab"},
{source: "24: potential products", target: "START_HERE", fill: "#0047ab"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Construction Materials</td>
    </tr>
    <tr>
      <td>Construction and Farm Machinery and Heavy Trucks</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>IT Consulting and Other Services</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Human Resource and Employment Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Material Aid</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Rally support</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Management_development">Management development</a></td>
      <td>Management development is the process by which managers learn and improve their management skills.\n\n\n== Background ==\nIn organisational development, management effectiveness is recognized as a determinant of organisational success.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Takeda_Oncology">Takeda Oncology</a></td>
      <td>Takeda Oncology (originally Millennium Pharmaceuticals) is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minimum_viable_product">Minimum viable product</a></td>
      <td>A minimum viable product (MVP) is a version of a product with just enough features to be usable by early customers who can then provide feedback for future product development.A focus on releasing an MVP means that developers potentially avoid lengthy and (ultimately) unnecessary work. Instead, they iterate on working versions and respond to feedback, challenging and validating assumptions about a product's requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MannKind_Corporation">MannKind Corporation</a></td>
      <td>MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Halozyme">Halozyme</a></td>
      <td>Halozyme Therapeutics is an American biotechnology company that develops novel oncology therapies designed to target the tumor microenvironment and licenses a novel drug delivery technology through corporate partnerships.\nThe company was founded in 1998 and went public in 2004.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Aerie_Pharmaceuticals">Aerie Pharmaceuticals</a></td>
      <td>Aerie Pharmaceuticals Inc. (Nasdaq: AERI) is a publicly traded, clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/MediGene">MediGene</a></td>
      <td>Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. Medigene is working on the development of immunotherapies to enhance T cell activity against solid cancers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Medicago_Inc.">Medicago Inc.</a></td>
      <td>Medicago Inc. is a privately-owned Canadian biotechnology company focused on the discovery, development, and commercialization of virus-like particles using plants as "bioreactors" to produce proteins as candidate vaccines and medications.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_of_the_2022_Australian_federal_election">Candidates of the 2022 Australian federal election</a></td>
      <td>This is a list of confirmed candidates in ballot paper order for the 2022 Australian federal election.At the close of nominations a total of 1,624 candidates had stood for election, of whom 1,203 were House of Representatives candidates and 421 were Senate candidates.\n\n\n== Retiring members ==\nThe seat of Spence (SA) was vacant following the resignation of Nick Champion (Labor) on 22 February 2022 to contest the South Australian state election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chemical_potential">Chemical potential</a></td>
      <td>In thermodynamics, the chemical potential of a species is the energy that can be absorbed or released due to a change of the particle number of the given species, e.g. in a chemical reaction or phase transition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Action_potential">Action potential</a></td>
      <td>In physiology, an action potential (AP) occurs when the membrane potential of a specific cell location rapidly rises and falls. This depolarization then causes adjacent locations to similarly depolarize.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Potential_energy">Potential energy</a></td>
      <td>In physics, potential energy is the energy held by an object because of its position relative to other objects, stresses within itself, its electric charge, or other factors.Common types of potential energy include the gravitational potential energy of an object that depends on its mass and its distance from the center of mass of another object, the elastic potential energy of an extended spring, and the electric potential energy of an electric charge in an electric field. The unit for energy in the International System of Units (SI) is the joule, which has the symbol J.\nThe term potential energy was introduced by the 19th-century Scottish engineer and physicist William Rankine, although it has links to Greek philosopher Aristotle's concept of potentiality.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Potential_superpower">Potential superpower</a></td>
      <td>A potential superpower is a state or a political and economic entity that is speculated to be—or to have the potential to soon become—a superpower.\nCurrently, only the United States fulfills the criteria to be considered a superpower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gravitational_potential">Gravitational potential</a></td>
      <td>In classical mechanics, the gravitational potential at a location is equal to the work (energy transferred) per unit mass that would be needed to move an object to that location from a fixed reference location. It is analogous to the electric potential with mass playing the role of charge.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ZYMOGENETICS INC      Item 1A    Risk Factors          Risks Related to Our Business          We have limited experience in developing or <font color="blue"><font color="blue">commercializing</font> products</font></td>
    </tr>
    <tr>
      <td>We have not yet fully developed or <font color="blue"><font color="blue">commercialize</font>d</font> any <font color="blue">products on</font> our own</td>
    </tr>
    <tr>
      <td>Our <font color="blue">contributions</font> to the <font color="blue">discovery</font> or <font color="blue">development</font> of <font color="blue">certain <font color="blue">therapeutic</font></font>     <font color="blue">proteins currently on</font> the market do not indicate that we will be                                           24     ______________________________________________________________________    [51]Table of <font color="blue">Contents       </font>able to <font color="blue">successfully</font> develop <font color="blue">products alone</font></td>
    </tr>
    <tr>
      <td>Our work relating to these     marketed  products  <font color="blue">generally</font>  did  not  include  clinical  trials  or     <font color="blue">manufacturing</font>, and we did not <font color="blue">participate</font> in marketing or other late-stage     <font color="blue">development</font> or <font color="blue"><font color="blue">commercialization</font> <font color="blue">activities</font></font></td>
    </tr>
    <tr>
      <td>We have limited experience with     product <font color="blue">development</font> <font color="blue">activities</font> and may not be successful in developing or     <font color="blue">commercializing</font> any products</td>
    </tr>
    <tr>
      <td>Any failure or delay in commencing or completing <font color="blue">clinical trials</font> for product     <font color="blue"><font color="blue">candidates</font> <font color="blue">could severely harm</font></font> our business</td>
    </tr>
    <tr>
      <td>The <font color="blue">successful <font color="blue">commercialization</font></font> of any <font color="blue">product <font color="blue">candidates</font></font> will <font color="blue">depend on</font>     <font color="blue"><font color="blue">regulatory</font> approval</font> in <font color="blue">each market</font> in which our <font color="blue">collaborators</font>, our licensees     or  we  intend  to  market the <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Each of our product     <font color="blue">candidates</font> must undergo extensive <font color="blue">non<font color="blue">clinical studies</font></font> and <font color="blue">clinical trials</font> as     a condition to <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td><font color="blue">Nonclinical </font>studies and <font color="blue">clinical trials</font>     are  time-consuming  and  expensive and together take <font color="blue">several years</font> to     complete, and to date we have not completed the <font color="blue">clinical testing</font> of any     <font color="blue"><font color="blue">product candidate</font> on</font> our own</td>
    </tr>
    <tr>
      <td>The <font color="blue">commencement</font> and <font color="blue">completion</font> of clinical     trials for our <font color="blue">product <font color="blue">candidates</font></font> may be <font color="blue">delayed by</font> many factors, including:           •   our <font color="blue">inability</font> or the <font color="blue">inability</font> of our <font color="blue">collaborators</font> or licensees to     <font color="blue">manufacture</font> or obtain <font color="blue">from <font color="blue">third parties</font> materials sufficient</font> for use in     <font color="blue">non<font color="blue">clinical studies</font></font> and <font color="blue">clinical trials</font>;           •   delays in <font color="blue">enrollment</font> of the number and types of patients required for     <font color="blue">clinical trials</font>;           •   <font color="blue"><font color="blue">difficult</font>y</font> in maintaining <font color="blue">contact with patients</font> after treatment,     resulting in <font color="blue">incomplete data</font>;           •   <font color="blue">in<font color="blue"><font color="blue">effective</font>ness</font></font> of <font color="blue">product <font color="blue">candidates</font></font> during the <font color="blue">clinical trials</font>;           •   <font color="blue">unforeseen safety issues</font> or side effects; and           •   <font color="blue"><font color="blue">government</font>al</font> or <font color="blue">regulatory</font> delays</td>
    </tr>
    <tr>
      <td>It is possible that none of our <font color="blue">product <font color="blue">candidates</font></font>, whether developed on our     own, with <font color="blue">collaborators</font> or by licensees, will complete <font color="blue">clinical trials</font> for     any of the markets in which we, our <font color="blue">collaborators</font> or <font color="blue">licensees intend</font> to     sell those <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Accordingly, our <font color="blue">collaborators</font>, our licensees     or we may not receive the <font color="blue"><font color="blue">regulatory</font> approval</font>s needed to market our product     <font color="blue">candidates</font> in any markets</td>
    </tr>
    <tr>
      <td>Any failure or delay in commencing or completing     <font color="blue">clinical trials</font> or obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s for our <font color="blue">product <font color="blue">candidates</font></font>     <font color="blue">could severely harm</font> our business</td>
    </tr>
    <tr>
      <td>Clinical <font color="blue"><font color="blue">trials may</font> fail</font> to <font color="blue">demonstrate</font> the safety and <font color="blue"><font color="blue">effective</font>ness</font> of our     product  <font color="blue">candidates</font>,  <font color="blue"><font color="blue">which could</font> prevent</font> or <font color="blue"><font color="blue"><font color="blue">significant</font>ly</font> delay</font> their     <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>Clinical <font color="blue">trials involving</font> our <font color="blue">product <font color="blue">candidates</font></font> may reveal that those     <font color="blue">candidates</font>  are  <font color="blue">in<font color="blue">effective</font></font>, have unacceptable toxicity or have other     unacceptable  side  effects</td>
    </tr>
    <tr>
      <td>In addition, data obtained <font color="blue">from tests</font> are     susceptible to varying <font color="blue">interpretation</font>s, which may delay, limit or prevent     <font color="blue"><font color="blue">regulatory</font> approval</font></td>
    </tr>
    <tr>
      <td>Likewise, the results of <font color="blue">preliminary</font> studies do not     predict clinical success, and larger and later-stage <font color="blue">clinical trials</font> may not     produce  the same results as earlier-stage trials</td>
    </tr>
    <tr>
      <td>Frequently, product     <font color="blue">candidates</font> that have <font color="blue">shown promising</font> results in early <font color="blue">clinical trials</font> have     <font color="blue">subsequently suffered <font color="blue">significant</font> setbacks</font> in later <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>In     addition, <font color="blue">clinical trials</font> of <font color="blue"><font color="blue">potential products</font> often</font> reveal that it is not     practical or feasible to continue <font color="blue">development</font> efforts for these product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may be unable to satisfy the <font color="blue"><font color="blue">rigorous <font color="blue">government</font> regulation</font>s</font> relating to     the <font color="blue">development</font> and <font color="blue">commercialization</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Any failure to receive the <font color="blue"><font color="blue">regulatory</font> approval</font>s necessary to <font color="blue">commercialize</font>     our  product  <font color="blue"><font color="blue">candidates</font> <font color="blue">could severely harm</font></font> our business</td>
    </tr>
    <tr>
      <td>Our product     <font color="blue">candidates</font> are subject to extensive and <font color="blue">rigorous <font color="blue">government</font> regulation</font></td>
    </tr>
    <tr>
      <td>The     FDA regulates, among other things, the collection, testing, <font color="blue">manufacturing</font>,     safety,  efficacy, potency, labeling, storage, record keeping, quality     systems, advertising, promotion, sale and <font color="blue">distribution</font> of <font color="blue">therapeutic</font>                                           25     ______________________________________________________________________    [52]Table of <font color="blue">Contents       </font>products</td>
    </tr>
    <tr>
      <td>If our <font color="blue">potential products</font> are <font color="blue">marketed abroad</font>, they will also be     subject to extensive <font color="blue">regulation by foreign <font color="blue">government</font>s</font></td>
    </tr>
    <tr>
      <td>None of our product     <font color="blue">candidates</font> has been approved for sale in the <font color="blue"><font color="blue">United States</font> </font>or any foreign     market,  and  we  have  only limited experience in filing and pursuing     <font color="blue"><font color="blue">applications</font> necessary</font> to gain <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> review and approval process, which includes nonclinical     studies and <font color="blue">clinical trials</font> of <font color="blue">each <font color="blue">product candidate</font></font>, is lengthy, expensive     and uncertain</td>
    </tr>
    <tr>
      <td><font color="blue">Securing FDA </font>approval requires the submission of extensive     nonclinical and <font color="blue">clinical data</font> and supporting information to the FDA for each     <font color="blue">indication</font> to establish the <font color="blue">product candidate</font>’s safety and <font color="blue"><font color="blue">effective</font>ness</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">approval process typically</font> takes many years to complete and <font color="blue">may involve</font>     <font color="blue">ongoing <font color="blue">requirements</font></font> for post-marketing studies</td>
    </tr>
    <tr>
      <td>In addition, we may not     achieve FDA approval of a <font color="blue"><font color="blue">product candidate</font> even</font> if we have met our internal     safety and <font color="blue">efficacy criteria</font> and completed <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>Also, any FDA or     other <font color="blue"><font color="blue">regulatory</font> approval</font> of our <font color="blue">product <font color="blue">candidates</font></font>, once obtained, may be     withdrawn</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font><font color="blue">regulation may</font> result in:           •   <font color="blue">prohibitions</font> or <font color="blue"><font color="blue">significant</font> delays</font> in the marketing of potential     products;           •   <font color="blue">discontinuation</font> of marketing of <font color="blue">potential products</font>; and           •   <font color="blue">limitations</font> of the <font color="blue">indicated uses</font> for which <font color="blue">potential products</font> may be     marketed</td>
    </tr>
    <tr>
      <td>If  we  fail to <font color="blue">comply with</font> the laws and <font color="blue"><font color="blue">regulations</font> pertaining</font> to our     business,  we  may be subject to sanctions, including the temporary or     <font color="blue">permanent suspension</font> of <font color="blue">operations</font>, product recalls, marketing <font color="blue">restrictions</font>     and civil and <font color="blue">criminal penalties</font></td>
    </tr>
    <tr>
      <td>Because we currently have only limited <font color="blue">capabilities</font> to <font color="blue">manufacture</font> materials     for <font color="blue">clinical trials</font> and <font color="blue">no <font color="blue">capability</font></font> for commercial scale <font color="blue">manufacturing</font>, we     will have to <font color="blue">rely <font color="blue">on <font color="blue">third parties</font></font></font> to <font color="blue">manufacture</font> our <font color="blue">potential products</font>,     and we may be unable to obtain required quantities in a <font color="blue">timely manner</font> or on     acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We currently do not have the <font color="blue">manufacturing</font> <font color="blue">facilities</font> necessary to produce     materials for <font color="blue">commercial sale</font>, and we have only limited <font color="blue">capabilities</font> to     produce materials for <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td>We intend to rely on <font color="blue">collaborators</font>     and third-party contract <font color="blue">manufacture</font>rs and suppliers to produce or provide     the quantities of <font color="blue">drug materials</font> needed for some of our <font color="blue">clinical trials</font> and     <font color="blue">commercialization</font> of our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>For example, we have contracted     with <font color="blue">Abbott Laboratories </font>to <font color="blue">manufacture</font> rhThrombin in bulk form for both     supply of <font color="blue">clinical trials</font> and eventual <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>In addition, there     are <font color="blue">several suppliers</font> of important <font color="blue">manufacturing</font> process intermediates and a     separate contract <font color="blue">manufacture</font>r for filling and finishing the <font color="blue">bulk product</font></td>
    </tr>
    <tr>
      <td>We  will  have to rely on these <font color="blue">manufacture</font>rs and suppliers to deliver     <font color="blue">materials on</font> a <font color="blue">timely basis</font> and to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue">requirements</font>,     including current GMP <font color="blue"><font color="blue">regulations</font> enforced by</font> the FDA through its <font color="blue">facilities</font>     <font color="blue">inspection program</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">manufacture</font>rs and <font color="blue">suppliers may</font> not be able to     meet our needs <font color="blue">with respect</font> to timing, quantity or quality of materials, and     may fail to satisfy applicable <font color="blue">regulatory</font> <font color="blue">requirements</font> <font color="blue">with respect</font> to the     <font color="blue">manufacturing</font> of these materials</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue"><font color="blue">agreement</font>s</font> that we have     <font color="blue"><font color="blue">entered into</font> with</font> third-party contract <font color="blue">manufacture</font>rs in the <font color="blue">past contain</font>,     and any contracts that we enter into with third-party contract <font color="blue">manufacture</font>rs     in the future may contain, <font color="blue">limitations</font> on the quantities of <font color="blue">drug materials</font>     that such <font color="blue">manufacture</font>rs will produce, and we may not be able to increase or     decrease the supply of <font color="blue">drug materials</font> based on unanticipated changes in     demand</td>
    </tr>
    <tr>
      <td>If we are unable to contract for a <font color="blue">sufficient supply</font> of needed     <font color="blue">materials on</font> acceptable terms, or if we <font color="blue">encounter delays</font> in the delivery of     <font color="blue">materials from</font>, or <font color="blue"><font color="blue">difficult</font>ies</font> in our relationships with, <font color="blue">manufacture</font>rs,     our IND-enabling <font color="blue">non<font color="blue">clinical studies</font></font> and <font color="blue">clinical trials</font> may be delayed</td>
    </tr>
    <tr>
      <td>Delays in <font color="blue">non<font color="blue">clinical studies</font></font> could postpone the filing of IND <font color="blue">applications</font>     or the <font color="blue">initiation</font> of <font color="blue">clinical trials</font>, and delays in <font color="blue">clinical trials</font> could     postpone the <font color="blue">subsequent submission</font> of <font color="blue">product <font color="blue">candidates</font></font> for <font color="blue">regulatory</font>     approval and <font color="blue">market introduction</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">manufacturing</font> <font color="blue">facility</font> has limited <font color="blue">capacity</font> and may not continue to     <font color="blue">comply with</font> applicable <font color="blue">manufacturing</font> <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Therapeutic </font>proteins are often more <font color="blue">difficult</font> and expensive to <font color="blue">manufacture</font>     than other classes of drugs, and their <font color="blue">manufacture</font> requires specialized     <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We completed <font color="blue">construction</font> in 2004 of an <font color="blue">expanded research</font> and                                           26     ______________________________________________________________________    [53]Table of <font color="blue">Contents       </font><font color="blue">development</font> <font color="blue">facility</font> that includes dedicated pilot-scale GMP <font color="blue">manufacturing</font>     suites for the production of <font color="blue">therapeutic</font> proteins for use in nonclinical and     <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>In October 2005, we <font color="blue">began production</font> of GMP material in     this <font color="blue">facility</font></td>
    </tr>
    <tr>
      <td>These initial <font color="blue">manufacturing</font> suites will not <font color="blue">provide us with</font>     the <font color="blue">capability</font> to produce <font color="blue">drug materials</font> for <font color="blue">commercial sale</font></td>
    </tr>
    <tr>
      <td>To develop     this <font color="blue">capability</font> we would need to acquire larger <font color="blue">manufacturing</font> <font color="blue">facilities</font>,     which are very expensive and require <font color="blue">extended periods</font> of time to build and     validate</td>
    </tr>
    <tr>
      <td>Also, we will be required to adhere to rigorous GMP <font color="blue">regulations</font> in     the <font color="blue">manufacture</font> of <font color="blue">therapeutic</font> proteins</td>
    </tr>
    <tr>
      <td>If any of our future <font color="blue">facilities</font> or     quality  systems  <font color="blue">cannot pass</font> a pre-approval plant inspection, the FDA     marketing  approval  of  our <font color="blue">product <font color="blue">candidates</font></font> may not be granted</td>
    </tr>
    <tr>
      <td>In     <font color="blue">complying with</font> these <font color="blue">regulations</font> and any applicable foreign <font color="blue">regulatory</font>     <font color="blue">requirements</font>, we will be obligated to expend time, money and effort in     production,  record  keeping  and <font color="blue">quality assurance</font> to assure that our     <font color="blue">potential products</font> meet applicable specifications and other <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Any failure to <font color="blue">comply with</font> these <font color="blue">requirements</font> may subject us to <font color="blue">regulatory</font>     sanctions and delay or interrupt our <font color="blue">development</font> and <font color="blue">commercialization</font>     efforts</td>
    </tr>
    <tr>
      <td>In addition, some of the <font color="blue"><font color="blue">inventions</font> licensed</font> to us were initially developed     <font color="blue">at universities</font> or other not-for-profit institutions with funding support     from an agency of the <font color="blue"><font color="blue">United States</font> </font><font color="blue">government</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">accordance with federal</font>     law, our licensees or we may be required to <font color="blue">manufacture</font> products <font color="blue">covered by</font>     patents in those <font color="blue">inventions</font> in the <font color="blue">United States</font>, unless we can obtain a     <font color="blue">waiver from</font> the <font color="blue">government</font> on the basis that such domestic <font color="blue">manufacture</font> is     not <font color="blue">commercially feasible</font></td>
    </tr>
    <tr>
      <td>We have not attempted to secure any <font color="blue">such waivers</font>     from the <font color="blue">government</font>, and do not know if they would be available if sought</td>
    </tr>
    <tr>
      <td>If we are not able to obtain <font color="blue">such waivers</font> on a <font color="blue">timely basis</font>, we might be     forced to seek <font color="blue">manufacturing</font> <font color="blue">arrangements</font> at higher prices, or <font color="blue">on otherwise</font>     less favorable terms, than might be available to us in the absence of this     domestic <font color="blue">manufacturing</font> requirement</td>
    </tr>
    <tr>
      <td>Because we <font color="blue">will depend <font color="blue">on <font color="blue">third parties</font></font></font> to <font color="blue">conduct certain <font color="blue">laboratory tests</font></font>     and <font color="blue">clinical trials</font>, we may <font color="blue">encounter delays</font> in or lose some <font color="blue">control over</font>     our efforts to develop <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>In <font color="blue">certain instances</font>, we will <font color="blue">rely <font color="blue">on <font color="blue">third parties</font></font></font> to design and conduct     <font color="blue">laboratory tests</font> and <font color="blue">clinical trials</font> for us</td>
    </tr>
    <tr>
      <td>If we are unable to obtain     these <font color="blue">services on</font> acceptable terms, we may not be able to complete our     product <font color="blue">development</font> efforts in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Also, because we will rely     <font color="blue">on <font color="blue">third parties</font></font> for <font color="blue">laboratory tests</font> and <font color="blue">clinical trials</font>, we may lose some     <font color="blue">control over</font> these <font color="blue">activities</font> or be unable to <font color="blue">manage them appropriately</font>, or     <font color="blue">may become too dependent on</font> these parties</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">third parties</font> may</font> not     complete the tests or <font color="blue">trials on schedule</font> or when we request, and the tests     or <font color="blue">trials may</font> be <font color="blue">methodologically flawed</font> or otherwise defective</td>
    </tr>
    <tr>
      <td>Any delays     or <font color="blue"><font color="blue">difficult</font>ies</font> associated with third-party <font color="blue">laboratory tests</font> or clinical     <font color="blue">trials may</font> delay the <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>we currently have no sales <font color="blue">capabilities</font> and limited marketing     <font color="blue">capabilities</font>, we may be unable to <font color="blue">successfully</font> <font color="blue">commercialize</font> our potential     products</td>
    </tr>
    <tr>
      <td>We  currently  have no direct sales <font color="blue">capabilities</font> and limited marketing     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We have stated our intention to market and <font color="blue">sell rhThrombin</font>     directly</td>
    </tr>
    <tr>
      <td>To do so, we will need to <font color="blue">incur <font color="blue">significant</font> <font color="blue">additional</font> expenses</font>     and commit <font color="blue">significant</font> <font color="blue">additional</font> <font color="blue">management</font> resources to develop <font color="blue">effective</font>     sales and marketing <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>We may not be able to establish these     <font color="blue">capabilities</font> despite these <font color="blue"><font color="blue">additional</font> <font color="blue">expenditure</font>s</font></td>
    </tr>
    <tr>
      <td>We also expect that in     the future we will rely on <font color="blue">collaborators</font> or other <font color="blue">third parties</font> to market     products that we may develop</td>
    </tr>
    <tr>
      <td>These <font color="blue"><font color="blue">third parties</font> may</font> not be successful in     marketing our <font color="blue">potential products</font>, and we will have little or no <font color="blue">control over</font>     their  <font color="blue">marketing efforts</font></td>
    </tr>
    <tr>
      <td>In addition, we may co-promote our potential     products or retain <font color="blue">marketing rights</font> in <font color="blue">North America </font>to these products</td>
    </tr>
    <tr>
      <td>Co-promotion  or  other  marketing  <font color="blue">arrangements</font> with <font color="blue">third parties</font> to     <font color="blue">commercialize</font> <font color="blue">potential products</font> could <font color="blue"><font color="blue">significant</font>ly</font> limit the revenues we     derive from these products</td>
    </tr>
    <tr>
      <td>Our  bioinformatics-based <font color="blue">discovery</font> strategy is unproven, and genes or     proteins we have <font color="blue">discovered may</font> have <font color="blue">no commercial value</font></td>
    </tr>
    <tr>
      <td>We  do  not  know whether our bioinformatics-based <font color="blue">therapeutic</font> protein     <font color="blue">discovery</font> strategy will yield commercially valuable products because our     bioinformatics-derived <font color="blue">product <font color="blue">candidates</font></font> are in the <font color="blue">early stages</font> of                                           27     ______________________________________________________________________    [54]Table of <font color="blue">Contents       </font><font color="blue">development</font></td>
    </tr>
    <tr>
      <td>For most of our <font color="blue">corporate existence</font>, we <font color="blue">relied on exploratory</font>     biology to <font color="blue">study particular diseases</font> and <font color="blue">medical <font color="blue">conditions</font></font> and to find     potential  <font color="blue">treatments</font></td>
    </tr>
    <tr>
      <td>We shifted our emphasis to bioinformatics-based     <font color="blue">discovery</font>  in the mid 1990s</td>
    </tr>
    <tr>
      <td><font color="blue">Bioinformatics </font>is the use of high-powered     computers, software and <font color="blue">analytical tools</font> to interpret DNA <font color="blue">sequence data</font> and     to assist in identifying those genes and proteins that are likely to play a     <font color="blue"><font color="blue">meaningful</font> role</font> in <font color="blue">human health</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">used bioinformatics</font> to discover     genes and their <font color="blue"><font color="blue">corresponding</font> proteins</font> in genomic databases, with the goal     of developing <font color="blue">therapeutic</font> protein-based products based on these <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>We have focused our <font color="blue">efforts on certain key protein <font color="blue">categories</font></font>, some of which     have <font color="blue">yielded successful products</font> in the past</td>
    </tr>
    <tr>
      <td>Prior successes of other     companies in <font color="blue">commercializing</font> protein-based products derived from these     <font color="blue">categories</font> provide no <font color="blue">indication</font> that we will be able to establish the     <font color="blue">medical utility</font> of any <font color="blue">therapeutic</font> <font color="blue">proteins with</font>in these <font color="blue"><font color="blue">categories</font> beyond</font>     those that have <font color="blue">already been</font> identified</td>
    </tr>
    <tr>
      <td>Also, <font color="blue">by focusing on specific</font>     <font color="blue">categories</font> of proteins, we may have overlooked other <font color="blue">therapeutic</font> proteins     not contained in these <font color="blue">categories</font> that <font color="blue">ultimately will</font> be <font color="blue">successfully</font>     <font color="blue"><font color="blue">commercialize</font>d</font> by others</td>
    </tr>
    <tr>
      <td>Our bioinformatics-based strategy may not     result in the successful <font color="blue">development</font> or <font color="blue">commercialization</font> of any products</td>
    </tr>
    <tr>
      <td>The lack of <font color="blue">novel genomic data</font> has required us to <font color="blue">pursue novel approaches</font> to     <font color="blue">discovering proteins</font> that may not yield new <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Since the mid-1990s we have relied on the flow of genomic data for the     <font color="blue">discovery</font> of <font color="blue">novel genes</font> and proteins</td>
    </tr>
    <tr>
      <td>With limited new genomic information,     we  have  shifted  our <font color="blue">discovery</font> efforts to <font color="blue">focus on <font color="blue">new approaches</font></font> to     <font color="blue">analyzing existing</font> information and to entirely new <font color="blue">discovery</font> approaches</td>
    </tr>
    <tr>
      <td>These <font color="blue">new approaches</font> are unproven and they may not result in the <font color="blue">discovery</font>     of any new <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>Our  patent  <font color="blue">applications</font>  may  not  result in <font color="blue">issued patents</font>, and our     <font color="blue"><font color="blue">competitors</font> may</font> <font color="blue">commercialize</font> the <font color="blue">discoveries</font> we attempt to patent</td>
    </tr>
    <tr>
      <td>Our pending patent <font color="blue">applications</font> covering genes and their <font color="blue">corresponding</font>     <font color="blue">proteins may</font> not result in the issuance of any patents</td>
    </tr>
    <tr>
      <td>These <font color="blue">applications</font>     may not be sufficient to meet the statutory <font color="blue">requirements</font> for <font color="blue">patentability</font>,     and therefore we may be unable to obtain <font color="blue">enforceable patents covering</font> the     related  <font color="blue">therapeutic</font>  protein-based  <font color="blue">product <font color="blue">candidates</font></font> we may want to     <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>In addition, other parties have filed or <font color="blue">may file patent</font>     <font color="blue">applications</font>  that  cover  genes,  proteins  or related <font color="blue">discoveries</font> or     <font color="blue">technologies</font>  similar  or  identical  to  those  covered in our patent     <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td><font color="blue">Because  </font>patent <font color="blue">applications</font> in the <font color="blue"><font color="blue">United States</font> </font>until     recently  have been maintained in <font color="blue">secrecy until</font> a <font color="blue">patent issues</font>, other     <font color="blue">parties may</font> have filed patent <font color="blue">applications</font> on genes or their <font color="blue">corresponding</font>     proteins before we filed <font color="blue">applications</font> covering the same genes or proteins,     and we may not be the first to discover these genes or proteins</td>
    </tr>
    <tr>
      <td>Any patent     <font color="blue">applications</font> filed by <font color="blue"><font color="blue">third parties</font> may</font> prevail over our patent <font color="blue">applications</font>     or may result in patents that <font color="blue">issue alongside patents issued</font> to us, leading     to <font color="blue"><font color="blue">uncertainty</font> over</font> the scope of the patents or the freedom to <font color="blue">practice with</font>     respect to the claimed <font color="blue">inventions</font></td>
    </tr>
    <tr>
      <td>Third  <font color="blue">parties may</font> infringe our patents or challenge their validity or     <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td>Third  parties  may  infringe  our patents or <font color="blue">may initiate <font color="blue">proceedings</font></font>     <font color="blue">challenging</font>  the scope, validity or <font color="blue">enforceability</font> of our patents</td>
    </tr>
    <tr>
      <td>The     issuance  of  a  patent is not <font color="blue">conclusive as</font> to its scope, validity or     <font color="blue">enforceability</font></td>
    </tr>
    <tr>
      <td><font color="blue">Challenges </font>raised in <font color="blue"><font color="blue">patent <font color="blue">infringement</font></font> <font color="blue">litigation</font></font> we     initiate  or  in  <font color="blue">proceedings</font> initiated by <font color="blue"><font color="blue">third parties</font> may</font> result in     <font color="blue">determinations</font> that our patents have not <font color="blue">been infringed</font> or that they are     invalid, unenforceable or otherwise subject to <font color="blue">limitations</font></td>
    </tr>
    <tr>
      <td>In the event of     any such <font color="blue">determinations</font>, <font color="blue"><font color="blue">third parties</font> may</font> be able to use the <font color="blue">discoveries</font> or     <font color="blue">technologies</font> claimed or described in our patents without paying licensing     fees or royalties to us, <font color="blue">which could</font> <font color="blue"><font color="blue">significant</font>ly</font> diminish the value of our     <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>In addition, enforcing our <font color="blue">patents against third</font>     <font color="blue">parties may</font> require <font color="blue"><font color="blue">significant</font> <font color="blue">expenditure</font>s regardless</font> of the outcome of     <font color="blue">such efforts</font></td>
    </tr>
    <tr>
      <td>Furthermore, <font color="blue"><font color="blue">third parties</font> may</font> <font color="blue">independently</font> develop <font color="blue">intellectual</font> property     similar to our patented <font color="blue">intellectual</font> property, <font color="blue">which could</font> result in, among     other things, <font color="blue">interference</font> <font color="blue">proceedings</font> in the <font color="blue"><font color="blue">United States</font> </font>                                          28     ______________________________________________________________________    [55]Table of <font color="blue">Contents       </font>Patent and Trademark Office to determine priority of <font color="blue">discovery</font> or invention</td>
    </tr>
    <tr>
      <td><font color="blue">Interference  </font><font color="blue">proceedings</font>  could  result in the loss of or <font color="blue">significant</font>     <font color="blue">limitations</font>  <font color="blue">on <font color="blue">patent protection</font></font> for our <font color="blue">discoveries</font> or <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td><font color="blue">Responding </font>to <font color="blue">interference</font> <font color="blue">proceedings</font> or other <font color="blue">challenges initiated by</font>     <font color="blue"><font color="blue">third parties</font> may</font> require <font color="blue">significant</font> <font color="blue">expenditure</font>s and divert the attention     of our <font color="blue">management</font> and <font color="blue"><font color="blue">key personnel</font> from</font> other business concerns</td>
    </tr>
    <tr>
      <td>We may be subject to <font color="blue">patent <font color="blue">infringement</font></font> claims, <font color="blue">which could</font> result in     substantial costs and <font color="blue">liability</font> and <font color="blue">prevent us from</font> <font color="blue">commercializing</font> our     <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Third <font color="blue">parties may</font> claim that our <font color="blue">potential products</font> processes or related     <font color="blue">technologies</font> infringe their patents</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font> is very common in the     <font color="blue">bio<font color="blue">pharmaceutical</font> industry</font>, and the risk of <font color="blue">infringement</font> claims is likely to     increase as the <font color="blue">industry continues</font> to expand and as other companies obtain     more patents and increase their efforts to <font color="blue">discover genes</font> and to develop     proteins</td>
    </tr>
    <tr>
      <td>Any <font color="blue">patent <font color="blue">infringement</font></font> claims or similar <font color="blue">legal impediments</font> that     might be <font color="blue">brought <font color="blue">against us</font> may</font> cause us to incur <font color="blue">significant</font> expenses,     divert the attention of our <font color="blue">management</font> and <font color="blue"><font color="blue">key personnel</font> from</font> other business     concerns  and,  if <font color="blue">successfully</font> asserted <font color="blue">against us</font>, require us to pay     substantial damages</td>
    </tr>
    <tr>
      <td>In addition, as a result of a <font color="blue">patent <font color="blue">infringement</font></font> suit,     we may be forced to stop or delay developing, <font color="blue">manufacturing</font> or selling     <font color="blue">potential products</font> that are claimed to infringe a <font color="blue">patent covering</font> a third     party’s <font color="blue">intellectual</font> property unless that <font color="blue">party grants us rights</font> to use its     <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>We may be unable to obtain these <font color="blue">rights on terms</font>     acceptable to us, if at all</td>
    </tr>
    <tr>
      <td>Even if we are able to obtain rights to a third     party’s patented <font color="blue">intellectual</font> property, these <font color="blue">rights may</font> be non-exclusive,     and therefore our <font color="blue"><font color="blue">competitors</font> may</font> be able to obtain access to the same     <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>Ultimately, we may be unable to <font color="blue">commercialize</font> our     <font color="blue">potential products</font> or may have to cease some of our business <font color="blue"><font color="blue">operations</font> as</font> a     result  of  patent  <font color="blue">infringement</font> claims, which <font color="blue">could severely harm</font> our     business</td>
    </tr>
    <tr>
      <td>Issued <font color="blue">patents may</font> not <font color="blue">provide us with</font> any <font color="blue">competitive advantage</font> or provide     <font color="blue"><font color="blue">meaningful</font> protection against <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>Issued <font color="blue">patents may</font> not <font color="blue">provide us with</font> any <font color="blue">competitive advantage</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although     </font>we have a number of <font color="blue">issued patents</font>, the <font color="blue">discoveries</font> or <font color="blue">technologies</font> covered     by these <font color="blue">patents may</font> not have any value</td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">issued patents</font> may not     provide  commercially <font color="blue"><font color="blue">meaningful</font> protection against <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Other     </font><font color="blue">parties may</font> be able to <font color="blue">design around</font> our <font color="blue">issued patents</font> or <font color="blue">independently</font>     develop products having effects similar or identical to our <font color="blue">patented product</font>     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>Some companies are <font color="blue">currently attempting</font> to develop <font color="blue">therapeutic</font>     protein-based products <font color="blue"><font color="blue">substantially</font> equivalent</font> to <font color="blue">products patented by</font>     other <font color="blue">parties by altering</font> the <font color="blue">amino acid sequence within</font> the <font color="blue">therapeutic</font>     protein-based product and declaring the <font color="blue">altered product</font> a new product</td>
    </tr>
    <tr>
      <td>It     may be easier to develop <font color="blue"><font color="blue"><font color="blue">substantially</font> equivalent</font> versions</font> of <font color="blue">therapeutic</font>     protein-based products such as monoclonal <font color="blue">antibodies</font> and <font color="blue">soluble <font color="blue">receptors</font></font>     than it is to develop <font color="blue"><font color="blue"><font color="blue">substantially</font> equivalent</font> versions</font> of the <font color="blue">proteins with</font>     which  they  interact because there is often more <font color="blue">than one antibody</font> or     receptor that has the same <font color="blue">therapeutic</font> effect</td>
    </tr>
    <tr>
      <td>Consequently, any existing or     future patents we have that cover monoclonal <font color="blue">antibodies</font> or <font color="blue">soluble <font color="blue">receptors</font></font>     may not provide any <font color="blue"><font color="blue">meaningful</font> protection against <font color="blue">competitors</font></font></td>
    </tr>
    <tr>
      <td>In addition,     the  scope  of  our patents is subject to considerable <font color="blue">uncertainty</font> and     <font color="blue">competitors</font> or other <font color="blue">parties may</font> obtain similar patents of <font color="blue">uncertain scope</font></td>
    </tr>
    <tr>
      <td>For example, other <font color="blue">parties may</font> discover uses for genes or <font color="blue">proteins <font color="blue">different</font></font>     from the uses covered in our patents, and these other uses may be <font color="blue">separately</font>     patentable</td>
    </tr>
    <tr>
      <td>If another party holds a patent on the use or <font color="blue">manufacture</font> of a     gene or protein, then even if we hold the <font color="blue">patent covering</font> the <font color="blue">composition</font> of     matter of the gene or <font color="blue">protein itself</font>, that other <font color="blue">party could <font color="blue">prevent us from</font></font>     selling any <font color="blue">product directed</font> to such use or using the <font color="blue">manufacturing</font> method     <font color="blue">covered by</font> the other party’s patent</td>
    </tr>
    <tr>
      <td>Also, other <font color="blue">parties may</font> have patents     covering the <font color="blue">composition</font> of matter of genes or proteins for which we have     patents covering only methods of use or methods of <font color="blue">manufacture</font> of these     genes or proteins</td>
    </tr>
    <tr>
      <td>Furthermore, the patents we hold relating to <font color="blue">recombinant</font>     human proteins, such as our patents covering rhThrombin, may not prevent     <font color="blue">competitors</font> from developing, <font color="blue">manufacturing</font> or selling other versions of     these  proteins</td>
    </tr>
    <tr>
      <td>Moreover,  although  we hold patents relating to the     <font color="blue">manufacture</font> of <font color="blue">recombinant</font> <font color="blue">human thrombin</font>, we have limited <font color="blue">composition</font> of     matter <font color="blue">patent protection</font> covering thrombin</td>
    </tr>
    <tr>
      <td>Accordingly, we may not be able     to prevent other parties from <font color="blue">commercializing</font> competing forms of <font color="blue">recombinant</font>     <font color="blue">human thrombin</font> or thrombin made through <font color="blue">different</font> <font color="blue">manufacturing</font> methods</td>
    </tr>
    <tr>
      <td>29     ______________________________________________________________________    [56]Table of <font color="blue">Contents       </font>The <font color="blue">patent field</font> relating to <font color="blue">therapeutic</font> protein-based products is subject     to a great deal of <font color="blue">uncertainty</font>, and if <font color="blue">patent laws</font> or the <font color="blue">interpretation</font> of     <font color="blue">patent laws</font> change, our <font color="blue"><font color="blue">competitors</font> may</font> be able to develop and <font color="blue">commercialize</font>     <font color="blue">products based on proteins</font> that we discovered</td>
    </tr>
    <tr>
      <td>The  patent  protection  available for genes, proteins and <font color="blue">therapeutic</font>     protein-based products is <font color="blue">highly uncertain</font> and <font color="blue">involves complex legal</font> and     factual questions that determine who has the right to develop a particular     product</td>
    </tr>
    <tr>
      <td>No <font color="blue">consistent case law</font> has emerged regarding the breadth of patents     in  this area</td>
    </tr>
    <tr>
      <td>There have been, and continue to be, <font color="blue">policy discussions</font>     <font color="blue">concerning</font> the scope of <font color="blue">patent protection</font> that should be awarded to genes     and their <font color="blue"><font color="blue">corresponding</font> proteins</font></td>
    </tr>
    <tr>
      <td>There <font color="blue">also continues</font> to be <font color="blue">policy concerns</font>     regarding the <font color="blue">enforceability</font> of patents covering research tools, which we     may  use  <font color="blue">during preclinical</font> or <font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>Social and political     opposition to patents on genes may lead to narrower <font color="blue">patent protection</font> for     genes and their <font color="blue"><font color="blue">corresponding</font> proteins</font></td>
    </tr>
    <tr>
      <td>Patent protection relating to genes     and <font color="blue">therapeutic</font> protein-based products is also subject to a great deal of     <font color="blue">uncertainty</font> outside the <font color="blue">United States</font>, and <font color="blue">patent laws</font> are evolving and     undergoing  revision  in  many  countries</td>
    </tr>
    <tr>
      <td><font color="blue">Changes  </font>in,  or <font color="blue">different</font>     <font color="blue">interpretation</font>s of, <font color="blue">patent laws</font> in the <font color="blue"><font color="blue">United States</font> </font>and other <font color="blue">countries may</font>     result in our <font color="blue">inability</font> to obtain <font color="blue">patent protection</font> for genes or proteins we     discover or to <font color="blue">enforce patents</font> that have <font color="blue">been issued</font> to us, and may allow     others to use our <font color="blue">discoveries</font> to develop and <font color="blue">commercialize</font> <font color="blue">therapeutic</font>     protein-based products</td>
    </tr>
    <tr>
      <td>We expect to incur <font color="blue">significant</font> expenses in applying for <font color="blue">patent protection</font>     and prosecuting our patent <font color="blue">applications</font></td>
    </tr>
    <tr>
      <td>We may fail to secure <font color="blue">meaningful</font> <font color="blue">patent protection</font> relating to any of our     existing or future <font color="blue">product <font color="blue">candidates</font></font>, <font color="blue">discoveries</font> or <font color="blue">technologies</font> despite     the <font color="blue">expenditure</font> of considerable resources</td>
    </tr>
    <tr>
      <td>Our success depends <font color="blue"><font color="blue">significant</font>ly</font>     on  the <font color="blue">establishment</font> of <font color="blue">patent protection</font> for the genes, proteins and     related <font color="blue">technologies</font> we discover or invent</td>
    </tr>
    <tr>
      <td>Consequently, we intend to     continue our substantial efforts in applying for <font color="blue">patent protection</font> and     <font color="blue">prosecuting pending</font> and future patent <font color="blue">applications</font> and maintaining patents</td>
    </tr>
    <tr>
      <td>These efforts have <font color="blue">historically</font> required the <font color="blue">expenditure</font> of considerable     time and money, and we expect that they <font color="blue">will continue</font> to require <font color="blue">significant</font>     <font color="blue">expenditure</font>s</td>
    </tr>
    <tr>
      <td>If future changes in <font color="blue"><font color="blue">United States</font> </font>or foreign <font color="blue">patent laws</font>     complicate or hinder our efforts to obtain <font color="blue">patent protection</font>, the costs     associated with patent <font color="blue">prosecution</font> may increase <font color="blue"><font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>We  may be unable to protect our <font color="blue">unpatented proprietary <font color="blue">technology</font></font> and     information</td>
    </tr>
    <tr>
      <td>In  addition  to  our  patented <font color="blue">intellectual</font> property, we <font color="blue">also rely on</font>     unpatented <font color="blue">technology</font>, trade secrets and <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>We may     not  be  able  to <font color="blue">effective</font>ly protect our rights to this <font color="blue">technology</font> or     information</td>
    </tr>
    <tr>
      <td>Other <font color="blue">parties may</font> <font color="blue">independently</font> develop equivalent <font color="blue">technologies</font>     or  <font color="blue">independently</font> gain access to and disclose <font color="blue"><font color="blue">substantially</font> equivalent</font>     information</td>
    </tr>
    <tr>
      <td>Disputes may arise <font color="blue">about inventorship</font> and <font color="blue">corresponding</font> rights     to know-how and <font color="blue">inventions</font> resulting from the <font color="blue">joint creation</font> or use of     <font color="blue">intellectual</font>  property  by  us  and our corporate partners, licensees,     scientific  and  academic  <font color="blue">collaborators</font> and <font color="blue">consultants</font></td>
    </tr>
    <tr>
      <td>In addition,     <font color="blue">confidential</font>ity <font color="blue"><font color="blue">agreement</font>s</font> and material <font color="blue">transfer <font color="blue"><font color="blue">agreement</font>s</font></font> we have entered     into with these parties and <font color="blue">with employees</font> and <font color="blue">advisors may</font> not provide     <font color="blue">effective</font> protection of our <font color="blue">technology</font> or information or, in the event of     <font color="blue">unauthorized use</font> or disclosure, may not <font color="blue">provide adequate remedies</font></td>
    </tr>
    <tr>
      <td>Our plan to <font color="blue">use <font color="blue">collaboration</font>s</font> to leverage our <font color="blue">capabilities</font> may not be     successful</td>
    </tr>
    <tr>
      <td>As  part  of our business strategy, we have <font color="blue"><font color="blue">entered into</font> <font color="blue">collaboration</font></font>     <font color="blue">arrangements</font> with strategic partners to co-develop <font color="blue">product <font color="blue">candidates</font></font> and     <font color="blue">will continue</font> to evaluate similar <font color="blue">opportunities</font></td>
    </tr>
    <tr>
      <td>For our <font color="blue">collaboration</font>     efforts to be successful, we must identify <font color="blue">partners whose competencies</font>     <font color="blue">complement</font>  ours</td>
    </tr>
    <tr>
      <td>We  must also <font color="blue">successfully</font> enter into <font color="blue">collaboration</font>     <font color="blue"><font color="blue"><font color="blue">agreement</font>s</font> with them on terms attractive</font> to us and integrate and coordinate     their resources and <font color="blue">capabilities</font> with our own</td>
    </tr>
    <tr>
      <td>We may be <font color="blue">unsuccessful</font> in     entering  into  <font color="blue">collaboration</font>  <font color="blue"><font color="blue">agreement</font>s</font>  with acceptable partners or     <font color="blue">negotiating</font>  favorable  terms  in  these  <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>Also, we may be     <font color="blue">unsuccessful</font>  in  <font color="blue">integrating</font>  the  resources or <font color="blue">capabilities</font> of these     <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">collaborators</font> may prove <font color="blue">difficult</font> to work     with or <font color="blue">less skilled than</font> we <font color="blue">originally</font> expected</td>
    </tr>
    <tr>
      <td>If we are <font color="blue">unsuccessful</font> in     our  <font color="blue">collaborative</font>  efforts, our ability to develop and <font color="blue">market product</font>     <font color="blue">candidates</font> could be severely limited</td>
    </tr>
    <tr>
      <td>30     ______________________________________________________________________    [57]Table of <font color="blue">Contents       </font>We may not be able to generate any revenue from <font color="blue">product <font color="blue">candidates</font></font> developed     by <font color="blue">collaborators</font> or licensees if they are unable to <font color="blue">successfully</font> develop     those <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We may be unable to derive any value from <font color="blue">product <font color="blue">candidates</font></font> developed by     <font color="blue">collaborators</font> or licensees</td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">generate <font color="blue">revenues from</font> existing</font>     or future <font color="blue">collaboration</font>s and license <font color="blue">arrangements</font> is subject to numerous     risks, including:           •   the <font color="blue">possibility</font> that our <font color="blue">collaborators</font> or licensees lack sufficient     financial, technical or other <font color="blue">capabilities</font> to develop these product     <font color="blue">candidates</font>;           •   the length of time that it takes for our <font color="blue">collaborators</font> or licensees to     achieve various clinical <font color="blue">development</font> and <font color="blue"><font color="blue">regulatory</font> approval</font> milestones;           •   the <font color="blue">inability</font> of <font color="blue">collaborators</font> or licensees to <font color="blue">successfully</font> address     any <font color="blue">regulatory</font> or <font color="blue">technical challenges</font> they <font color="blue">may encounter</font>; and           •   the <font color="blue">possibility</font> that these <font color="blue">product <font color="blue">candidates</font></font> may not be <font color="blue">effective</font> or     may prove to have undesirable side effects, unacceptable toxicities or other     <font color="blue">characteristics</font> that preclude <font color="blue"><font color="blue">regulatory</font> approval</font> or prevent or limit     <font color="blue">commercial use</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">collaborators</font> or <font color="blue">licensees may merge</font> or be acquired and a     <font color="blue">new company may</font> not be willing to continue the <font color="blue">collaboration</font></td>
    </tr>
    <tr>
      <td>For example,     Serono announced in November 2005 that it had retained an <font color="blue"><font color="blue">investment</font> bank</font> to     <font color="blue">explore various strategic alternatives</font> for the company</td>
    </tr>
    <tr>
      <td>Although we are not     aware of the outcome of this strategic review, if Serono were to <font color="blue">merge with</font>     or be acquired by another company, the <font color="blue">successor company may choose</font> to scale     back  or <font color="blue">discontinue</font> its co-<font color="blue">development</font> <font color="blue">activities</font> under the strategic     <font color="blue">alliance <font color="blue">agreement</font></font> or the <font color="blue">development</font> and <font color="blue">marketing <font color="blue">agreement</font></font> for TACI-Ig     that we have <font color="blue"><font color="blue">entered into</font> with</font> Serono, <font color="blue">which could</font> harm our business</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Novo Nordisk </font>and Serono </font>have substantial rights to <font color="blue">license proteins</font> we     discover, which may limit our ability to pursue other <font color="blue">collaboration</font> or     licensing <font color="blue">arrangements</font> or maximize the <font color="blue">benefit from</font> our <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>As part of our <font color="blue">separation from</font> Novo Nordisk, we granted <font color="blue">Novo Nordisk </font>options     to <font color="blue">license certain rights</font> to several of our potential <font color="blue">therapeutic</font> proteins     under an <font color="blue">option <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>Although we <font color="blue">generally</font> retain <font color="blue">North American     </font>rights to the proteins licensed by <font color="blue">Novo Nordisk </font>pursuant to this <font color="blue">agreement</font>,     <font color="blue">Novo Nordisk </font>has rights to these proteins in the rest of the world</td>
    </tr>
    <tr>
      <td>In     addition, under this <font color="blue">agreement</font> <font color="blue">Novo Nordisk </font>has <font color="blue">worldwide rights</font>, including     rights in North America, to any <font color="blue">licensed proteins</font> that act to generate,     expand or prevent the death of insulin-producing beta cells</td>
    </tr>
    <tr>
      <td><font color="blue">Novo Nordisk </font>    has <font color="blue"><font color="blue">already licensed</font> five proteins</font>, and it may license other proteins in the     <font color="blue">future pursuant</font> to this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>In 2004 we <font color="blue">entered into</font> a strategic <font color="blue">alliance <font color="blue">agreement</font></font> with Serono, pursuant     to which we granted Serono options to <font color="blue">license certain rights</font> to proteins in     our <font color="blue">research pipeline</font></td>
    </tr>
    <tr>
      <td>Although we retained the rights to co-develop and     co-<font color="blue">commercialize</font> the <font color="blue">licensed proteins</font> in the <font color="blue">United States</font>, Serono has at     <font color="blue">least half interest</font> in the <font color="blue"><font color="blue">United States</font> </font>rights and full rights to these     <font color="blue">proteins outside</font> the <font color="blue">United States</font>, subject to the rights of <font color="blue">Novo Nordisk </font>    under the above described <font color="blue">option <font color="blue">agreement</font></font></td>
    </tr>
    <tr>
      <td>Serono has <font color="blue">already licensed</font>     three  proteins as part of the <font color="blue">strategic alliance</font>, for one of which we     elected to pursue co-<font color="blue">development</font>, and it may license other proteins in the     <font color="blue">future pursuant</font> to this <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">agreement</font>s</font> with <font color="blue"><font color="blue">Novo Nordisk </font>and Serono </font>may:           •   preclude or delay <font color="blue">opportunities</font> to seek other <font color="blue">collaborators</font> for our     <font color="blue">product <font color="blue">candidates</font></font>, due to the fact that we <font color="blue">cannot explore</font> other     <font color="blue">collaboration</font> <font color="blue">opportunities</font> relating to proteins subject to the <font color="blue"><font color="blue">agreement</font>s</font>     until after <font color="blue">Novo Nordisk </font>and/or Serono has decided not to exercise an option     <font color="blue">with respect</font> to the protein;           •       limit the <font color="blue">financial benefits</font> we may derive from <font color="blue">product <font color="blue">candidates</font></font> by     allowing <font color="blue">Novo Nordisk </font>and/or Serono to <font color="blue">license proteins</font> in exchange for     <font color="blue">predetermined</font> payments and royalties and with <font color="blue">predetermined</font> cost-sharing     <font color="blue">arrangements</font>, which payments and royalty rates may be less than, and                                           31     ______________________________________________________________________    [58]Table of <font color="blue">Contents       </font>    which cost-sharing <font color="blue">arrangements</font> may be less favorable to us than, terms we     <font color="blue">might otherwise</font> obtain in <font color="blue">collaborative</font> or licensing <font color="blue">arrangements</font> with other     parties;           •   result in <font color="blue">Novo Nordisk </font>and/or Serono licensing <font color="blue">proteins with</font> the most     <font color="blue">therapeutic</font> and commercial potential, leaving us with fewer or less     desirable <font color="blue">product <font color="blue">candidates</font></font> to develop on our own or with other potential     <font color="blue">collaborators</font>; and           •   <font color="blue"><font color="blue">prevent us from</font> collaborating with</font> or licensing a <font color="blue">product candidate</font> to     another company that, by virtue of its <font color="blue">particular skills</font> and <font color="blue">capabilities</font>,     may be a more <font color="blue">desirable collaborator</font> or <font color="blue">licensing partner</font> for that     particular <font color="blue">product candidate</font> than <font color="blue">Novo Nordisk </font>or SeroNodtta         Environmental and health and safety laws may result in <font color="blue">liabilities</font>, expenses     and <font color="blue">restrictions</font> on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>State  and  federal laws regarding <font color="blue"><font color="blue">environment</font>al</font> protection, <font color="blue">hazardous</font>     substances and <font color="blue">human health</font> and safety may <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>The use of <font color="blue">hazardous</font> substances in our <font color="blue">operations</font> exposes us to the risk of     <font color="blue">accidental</font>  releases</td>
    </tr>
    <tr>
      <td>If our <font color="blue">operations</font> result in <font color="blue">contamination</font> of the     <font color="blue">environment</font> or <font color="blue">expose individuals</font> to <font color="blue">hazardous</font> substances, we could be     liable for damages and fines</td>
    </tr>
    <tr>
      <td>Future changes to <font color="blue"><font color="blue">environment</font>al</font> and health and     <font color="blue">safety laws could</font> cause us to <font color="blue">incur <font color="blue">additional</font> expenses</font> or restrict our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In addition, the site where our <font color="blue">principal headquarters</font> and     <font color="blue">facilities</font> are located has <font color="blue">been listed as</font> a <font color="blue">contaminated property by</font> the     <font color="blue">State of Washington </font>due to its <font color="blue">previous use by</font> the <font color="blue"><font color="blue">City of Seattle</font> </font>as an     <font color="blue">electricity generating plant</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">City of Seattle</font> </font>has agreed to <font color="blue">defend us</font>     against and <font color="blue">indemnify us</font> for any claims that arise from this pre-existing     <font color="blue">contamination</font>, except to the extent that we caused the claim through our     negligence or <font color="blue">intentional fault</font>, or to the extent that we <font color="blue">contributed</font> to the     <font color="blue">contamination</font> that is the subject of the claim, caused an increase in the     clean-up costs or failed to <font color="blue">comply with</font> our <font color="blue"><font color="blue">obligations</font> under</font> our <font color="blue">agreement</font>     with the <font color="blue">City of Seattle</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">indemnity may</font> be insufficient and we may be     subject  to  <font color="blue"><font color="blue">environment</font>al</font>  <font color="blue">liabilities</font> or be <font color="blue">prohibited from using</font> or     occupying some or all of the <font color="blue">property as</font> a result of <font color="blue"><font color="blue">environment</font>al</font> claims</td>
    </tr>
    <tr>
      <td><font color="blue">Natural  </font>or  man-made  <font color="blue">disasters</font> may impair our ability to conduct our     business</td>
    </tr>
    <tr>
      <td>Our company operates from a <font color="blue">single location</font> in Seattle, Washington, which     may be subject to natural or man-made <font color="blue">disasters</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">disasters</font> could cause     damage to our <font color="blue">facility</font>, personnel or equipment, which in turn, could cause     us to cease or curtail <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our business and <font color="blue">financial position may</font>     also  be  affected by <font color="blue">disasters</font> affecting the <font color="blue">operations</font> of one of our     partners, <font color="blue">manufacture</font>rs or suppliers</td>
    </tr>
    <tr>
      <td><font color="blue">Disasters </font>may include, but are not     limited to earthquakes, tsunamis, fires, floods, power loss, communication     failures and other similar events, including the effects of war or acts of     terrorism</td>
    </tr>
    <tr>
      <td>If  any disaster were to occur, our ability to operate our     business could be seriously or <font color="blue">completely</font> impaired</td>
    </tr>
    <tr>
      <td>Although we maintain     <font color="blue">insurance coverage</font> for many of these types of risks, it may not be adequate     to  cover  our  losses  resulting  from  <font color="blue">disasters</font>  or  other business     <font color="blue">interruptions</font></td>
    </tr>
    <tr>
      <td>Financial and Market Risks          We anticipate <font color="blue">incurring <font color="blue">additional</font> losses</font> and may not achieve <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an <font color="blue">accumulated deficit</font> of dlra367dtta8 million</td>
    </tr>
    <tr>
      <td>We     expect to continue to <font color="blue">incur increasing losses over</font> the next <font color="blue">several years</font>,     and we <font color="blue">may never become profitable</font></td>
    </tr>
    <tr>
      <td>It will be a number     of years before we <font color="blue">generate <font color="blue">revenues from</font> sales</font> of other <font color="blue">potential products</font>,     if ever</td>
    </tr>
    <tr>
      <td>Our <font color="blue">revenues from</font> existing <font color="blue">collaborative</font> and licensing <font color="blue">arrangements</font>     are insufficient to cover our operating expenses, and we <font color="blue">may never generate</font>     <font color="blue">revenues from</font> these or any future <font color="blue">arrangements</font> sufficient to cover these     expenses</td>
    </tr>
    <tr>
      <td>In addition, we <font color="blue">will continue</font> to incur substantial expenses     relating to our research and <font color="blue">development</font> efforts</td>
    </tr>
    <tr>
      <td>We anticipate that these     <font color="blue">expenses will increase as</font> we focus on the <font color="blue">laboratory tests</font> and clinical     trials required to obtain the <font color="blue"><font color="blue">regulatory</font> approval</font>s necessary for the sale of     any  products</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of our <font color="blue">product <font color="blue">candidates</font></font> will require     <font color="blue">significant</font> further research, <font color="blue">development</font>, testing and <font color="blue"><font color="blue">regulatory</font> approval</font>s</td>
    </tr>
    <tr>
      <td>We may not be able to complete such <font color="blue">development</font> or succeed in developing     products  that  will  <font color="blue">generate revenues</font> that <font color="blue">will justify</font> the costs of     <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>32     ______________________________________________________________________    [59]Table of <font color="blue">Contents       </font>If we do not obtain substantial <font color="blue"><font color="blue">additional</font> funding on</font> acceptable terms, we     may not be able to continue to grow our business or <font color="blue">generate enough revenue</font>     to recover our <font color="blue">investment</font> in research and <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Our business does not <font color="blue">currently generate</font> the cash needed to finance our     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We anticipate that we <font color="blue">will continue</font> to expend substantial funds     on our research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We expect that these <font color="blue">expenditure</font>s     will increase <font color="blue"><font color="blue">significant</font>ly</font> over the next <font color="blue">several years</font> as we continue to     <font color="blue">hire <font color="blue">additional</font> employees</font> and expand our clinical <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>We     will need to <font color="blue">seek <font color="blue">additional</font> funding through public</font> or <font color="blue">private financings</font>,     including <font color="blue">equity financings</font>, and through other <font color="blue">arrangements</font>, including     <font color="blue">collaborative</font>  and  licensing  <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>Poor  financial results,     <font color="blue">unanticipated expenses</font> or unanticipated <font color="blue">opportunities</font> that require financial     <font color="blue">commitments could give rise</font> to <font color="blue">additional</font> financing <font color="blue">requirements</font> sooner than     we expect</td>
    </tr>
    <tr>
      <td>However, <font color="blue">financing may</font> be unavailable when we need it or may not     be <font color="blue">available on</font> acceptable terms</td>
    </tr>
    <tr>
      <td>If we <font color="blue"><font color="blue">raise <font color="blue">additional</font></font> funds by issuing</font>     equity or <font color="blue">convertible debt securities</font>, the <font color="blue">percentage ownership</font> of our     <font color="blue">existing <font color="blue">shareholders</font> will</font> be diluted, and these <font color="blue">securities may</font> have rights     superior to those of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">raise <font color="blue">additional</font></font>     funds  when  we  need them, we may be required to delay, scale back or     eliminate <font color="blue">expenditure</font>s for some of our research or <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>We     may also be required to <font color="blue">grant rights</font> to <font color="blue">third parties</font> to develop and market     <font color="blue">product <font color="blue">candidates</font></font> that we <font color="blue">would prefer</font> to develop and <font color="blue">market internally</font>,     and such <font color="blue">rights may</font> be <font color="blue">granted on terms</font> that are not favorable to us</td>
    </tr>
    <tr>
      <td>If we     were required to <font color="blue">grant such rights</font>, the <font color="blue">ultimate value</font> of these product     <font color="blue">candidates</font> to us would be reduced</td>
    </tr>
    <tr>
      <td>Our operating results are subject to <font color="blue">fluctuations</font> that may cause our stock     price to decline</td>
    </tr>
    <tr>
      <td>Our revenues are unpredictable and <font color="blue">may fluctuate due</font>     to the timing of <font color="blue">licensing fees</font> or the <font color="blue">achievement</font> of <font color="blue">milestones under new</font>     or <font color="blue">existing licensing</font> and <font color="blue">collaborative</font> <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>In addition, our     expenses  may  fluctuate  <font color="blue">from quarter</font> to <font color="blue">quarter due</font> to the timing of     expenses, particularly <font color="blue">with respect</font> to contract <font color="blue">manufacturing</font> and clinical     and non<font color="blue">clinical testing</font></td>
    </tr>
    <tr>
      <td>We believe that period-to-period comparisons of our     past operating results are not good <font color="blue">indicators</font> of our future performance and     should not be relied on to predict our future operating results</td>
    </tr>
    <tr>
      <td>It is     possible that in the future our operating results in a <font color="blue">particular quarter</font> or     <font color="blue">quarters will</font> not meet the <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or investors,     causing the <font color="blue">market price</font> of our <font color="blue">common stock</font> to decline</td>
    </tr>
    <tr>
      <td>Risks Related to Our Industry          Many  of  our  <font color="blue">competitors</font> have <font color="blue">substantially</font> greater <font color="blue">capabilities</font> and     resources than we do and may be able to develop and <font color="blue">commercialize</font> products     before we do</td>
    </tr>
    <tr>
      <td>We may be unable to compete <font color="blue">successfully</font> against our current or future     <font color="blue">competitors</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">competition</font> in our field <font color="blue">will continue</font> to be     intense</td>
    </tr>
    <tr>
      <td>We face <font color="blue">competition</font> from other <font color="blue">entities involved</font> in the research     and <font color="blue">development</font> of <font color="blue">therapeutic</font> proteins, including Genentech, Inc, Human     Genome Sciences, Inc, Curagen, Inc</td>
    </tr>
    <tr>
      <td>We also face <font color="blue">competition</font>     <font color="blue">from entities</font> developing other types of products related to particular     diseases,  including other bio<font color="blue">technology</font> and <font color="blue"><font color="blue">pharmaceutical</font> companies</font></td>
    </tr>
    <tr>
      <td>Furthermore, our <font color="blue">potential products</font>, if approved and <font color="blue"><font color="blue">commercialize</font>d</font>, may     compete  against  well-established  existing <font color="blue">therapeutic</font> protein-based     products, many of which may be currently reimbursed by <font color="blue">government</font> health     administration authorities, private health insurers and <font color="blue">health maintenance</font>     <font color="blue">organizations</font></td>
    </tr>
    <tr>
      <td>Assuming we are successful in obtaining <font color="blue">marketing approval</font> for rhThrombin in     the <font color="blue">United States</font>, we expect it to face substantial <font color="blue">competition</font> both from     <font color="blue">currently market</font>ed plasma-derived thrombin products and from those presently     under <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In the <font color="blue">United States</font>, the only stand-alone thrombin     product  on  the  market  is  Thrombin-JMI,  which  is  sold  by  King     Pharmaceuticals, Inc</td>
    </tr>
    <tr>
      <td>rhThrombin’s market potential may be limited if, in     <font color="blue">clinical studies</font>, we are unable to <font color="blue">demonstrate</font> any <font color="blue">safety advantages over</font>     Thrombin-JMI  Other  plasma-derived  products that <font color="blue">would compete with</font>     rhThrombin are presently in <font color="blue">development</font>, including <font color="blue">bovine thrombin</font> developed     by  Vascular Solutions, Inc</td>
    </tr>
    <tr>
      <td>and <font color="blue">human thrombin</font> developed by Johnson &amp;     Johnson  and  OMRIX  Bio<font color="blue"><font color="blue">pharmaceutical</font>s</font>, Inc</td>
    </tr>
    <tr>
      <td>Furthermore, a number of     companies, including Johnson &amp; Johnson and Baxter, <font color="blue">currently market</font> other     <font color="blue">hemostatic agents</font> that may present <font color="blue">additional</font> <font color="blue">competition</font> to rhThrombin</td>
    </tr>
    <tr>
      <td>33     ______________________________________________________________________    [60]Table of <font color="blue">Contents       </font>Many of our existing and potential <font color="blue">competitors</font> have <font color="blue">substantially</font> greater     research and product <font color="blue">development</font> <font color="blue">capabilities</font> and financial, scientific,     marketing and human resources than we do</td>
    </tr>
    <tr>
      <td>As a result, these <font color="blue">competitors</font>     may:           •   succeed in identifying genes or proteins, or developing <font color="blue">therapeutic</font>     protein-based products, earlier than we do;           •   obtain approvals for products from the FDA or other <font color="blue">regulatory</font>     agencies more <font color="blue">rapidly than</font> we do;           •   obtain patents that block or <font color="blue">otherwise inhibit</font> our ability to develop     and <font color="blue">commercialize</font> our <font color="blue">product <font color="blue">candidates</font></font>;           •   develop <font color="blue">treatments</font> or cures that are safer or more <font color="blue">effective</font> than     those we propose to develop;           •   <font color="blue">devote greater resources</font> to marketing or selling their products;           •   introduce or adapt more quickly to new <font color="blue">technologies</font> or scientific     advances, <font color="blue">which could</font> render our <font color="blue">discovery</font> <font color="blue">technologies</font> obsolete;           •   <font color="blue">introduce products</font> that make the continued <font color="blue">development</font> of our     <font color="blue">potential products</font> uneconomical;           •   withstand price <font color="blue">competition</font> more <font color="blue">successfully</font> than we can;           •   more <font color="blue">effective</font>ly negotiate third-party <font color="blue">collaborative</font> or licensing     <font color="blue">arrangements</font>; and           •   take advantage of <font color="blue">acquisition</font> or other <font color="blue">opportunities</font> more <font color="blue">readily than</font>     we can</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font>, even if <font color="blue">approved by</font> the FDA or foreign <font color="blue">regulatory</font>     agencies, may not achieve market <font color="blue">acceptance</font> among hospitals, insurers or     patients</td>
    </tr>
    <tr>
      <td>Our <font color="blue">product <font color="blue">candidates</font></font>, even if <font color="blue">approved by</font> the FDA or foreign <font color="blue">regulatory</font>     agencies, may fail to achieve market <font color="blue">acceptance</font>, which would impair our     ability to become profitable</td>
    </tr>
    <tr>
      <td>We believe that market <font color="blue">acceptance</font> of our     <font color="blue">potential products</font> will <font color="blue">depend on</font> our ability to provide acceptable evidence     of safety, efficacy and limited side effects, our ability to provide these     <font color="blue">potential products</font> at reasonable prices and the <font color="blue">availability</font> of third-party     <font color="blue">reimbursement</font> for these <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>In addition, market <font color="blue">acceptance</font>     <font color="blue">depends on</font> the <font color="blue"><font color="blue">effective</font>ness</font> of our sales and marketing <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>To     date,  we  have  no  direct  sales  <font color="blue">capabilities</font> and limited marketing     <font color="blue">capabilities</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">health care</font> system, <font color="blue">reimbursement</font> policies or any other <font color="blue">health care</font>     related <font color="blue">regulations</font> change, the prices of our <font color="blue">potential products</font> may fall or     our <font color="blue">potential sales may decline</font></td>
    </tr>
    <tr>
      <td>In recent years, officials have made <font color="blue">numerous proposals</font> to change the health     <font color="blue">care system</font> in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>These proposals include measures that     would  limit  or  <font color="blue">prohibit payments</font> for <font color="blue">certain medical procedures</font> and     <font color="blue">treatments</font> or subject the pricing of <font color="blue"><font color="blue">pharmaceutical</font>s</font> to <font color="blue">government</font> control</td>
    </tr>
    <tr>
      <td><font color="blue">Government </font>and other third-party payors increasingly have attempted to     control  health  <font color="blue">care costs by limiting both coverage</font> and the level of     <font color="blue">reimbursement</font>  of  newly  approved <font color="blue">health care</font> products</td>
    </tr>
    <tr>
      <td>Increasingly,     third-party payors have been <font color="blue">challenging</font> the <font color="blue">prices charged</font> for products</td>
    </tr>
    <tr>
      <td>They <font color="blue">may also refuse</font> to provide any coverage of uses of <font color="blue">approved products</font>     for medical <font color="blue">indication</font>s other than those for which the FDA has granted     <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">government</font> may adopt future legislative proposals,     <font color="blue">such as price controls on <font color="blue">prescription</font> drugs</font>, and federal, state or private     payors for <font color="blue">health care</font> goods and services may take <font color="blue">further action</font> to limit     payments for <font color="blue">health care</font> products and services</td>
    </tr>
    <tr>
      <td>In addition, in certain     foreign countries, particularly the countries of the European Union, the     pricing of <font color="blue">prescription</font> <font color="blue"><font color="blue">pharmaceutical</font>s</font> is subject to <font color="blue"><font color="blue">government</font>al</font> control</td>
    </tr>
    <tr>
      <td>Any of these factors could limit our ability to <font color="blue">successfully</font> <font color="blue">commercialize</font>     our <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>We may face increased <font color="blue">competition</font> from lower priced products re-imported     into the <font color="blue"><font color="blue">United States</font> </font>from Canada and other countries</td>
    </tr>
    <tr>
      <td>The <font color="blue">current law</font>,     enacted in <font color="blue">December </font>2003, allows the <font color="blue">importation</font> of <font color="blue">drugs from</font> Canada, but     only  if  the  <font color="blue">Secretary  </font>of  <font color="blue">Health and Human Services </font>certifies that     <font color="blue">importation</font> will pose no <font color="blue">additional</font> risk to the public’s health and safety</td>
    </tr>
    <tr>
      <td>To date, no such <font color="blue">certification</font>s have <font color="blue">been given</font></td>
    </tr>
    <tr>
      <td><font color="blue">Legislative </font>proposals have                                           34     ______________________________________________________________________    [61]Table of <font color="blue">Contents       </font>been made to change the law to allow <font color="blue">importation</font> without any <font color="blue">certification</font></td>
    </tr>
    <tr>
      <td>If this or other <font color="blue">new legislation</font> or <font color="blue">regulations</font> were <font color="blue">passed allowing</font> the     re<font color="blue">importation</font>  of  drugs,  it could <font color="blue">adversely</font> affect the prices of our     <font color="blue">potential products</font></td>
    </tr>
    <tr>
      <td>Negative <font color="blue">public opinion</font> and increased <font color="blue">regulatory</font> scrutiny of genetic and     <font color="blue">clinical research may limit</font> our ability to conduct our business</td>
    </tr>
    <tr>
      <td>Ethical, social and <font color="blue">legal concerns about genetic</font> and <font color="blue">clinical research could</font>     result in <font color="blue">additional</font> <font color="blue">regulations</font> restricting or prohibiting some of our     <font color="blue">activities</font> or the <font color="blue">activities</font> of our suppliers and <font color="blue">collaborators</font></td>
    </tr>
    <tr>
      <td>In recent     years, federal and state agencies, congressional committees and foreign     <font color="blue">government</font>s have expressed interest in <font color="blue">further regulating</font> the bio<font color="blue">technology</font>     industry</td>
    </tr>
    <tr>
      <td>More restrictive <font color="blue">regulations</font> could delay <font color="blue">non<font color="blue">clinical studies</font></font> or     future <font color="blue">clinical trials</font>, or <font color="blue">prevent us from</font> obtaining <font color="blue"><font color="blue">regulatory</font> approval</font>s or     <font color="blue">commercializing</font> any products</td>
    </tr>
    <tr>
      <td>In addition, animal rights activists may     protest our use of animals in research and <font color="blue">development</font> and <font color="blue">may attempt</font> to     disrupt our <font color="blue">operations</font>, <font color="blue">which could</font> cause us to incur <font color="blue">significant</font> expenses     and distract our <font color="blue">management</font>’s attention from other business concerns</td>
    </tr>
    <tr>
      <td>The failure to attract or retain key <font color="blue">management</font> or other <font color="blue">personnel could</font>     decrease  our ability to discover, develop and <font color="blue">commercialize</font> potential     products</td>
    </tr>
    <tr>
      <td>We  <font color="blue">depend on</font> our <font color="blue">senior <font color="blue">executive officers</font> as well as key scientific</font>,     <font color="blue">management</font> and other personnel</td>
    </tr>
    <tr>
      <td>Only a few of our <font color="blue">key personnel</font> are bound by     <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font>, and those with <font color="blue">employment</font> <font color="blue"><font color="blue">agreement</font>s</font> are bound only     for a limited period of time</td>
    </tr>
    <tr>
      <td>Further, we have not purchased key-person life     <font color="blue">insurance policies</font> for any of our <font color="blue">executive officers</font> or <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>for <font color="blue">scientists</font> and other qualified employees is <font color="blue">intense among</font>     <font color="blue">pharmaceutical</font>  and bio<font color="blue">technology</font> companies, and the loss of qualified     employees, or an <font color="blue">inability</font> to attract, retain and motivate the <font color="blue">additional</font>     <font color="blue">highly skilled employees</font> required for the expansion of our <font color="blue">activities</font>, could     hinder  our  ability  to discover, develop and <font color="blue">commercialize</font> potential     products</td>
    </tr>
    <tr>
      <td>We may be required to <font color="blue">defend lawsuits</font> or pay damages in <font color="blue">connection with</font>     alleged or <font color="blue">actual harm</font> caused by our <font color="blue">product <font color="blue">candidates</font></font></td>
    </tr>
    <tr>
      <td>We face an inherent business risk of exposure to product <font color="blue">liability</font> claims in     the event that the use of our <font color="blue">product <font color="blue">candidates</font></font> is alleged to have resulted     in  harm  to others</td>
    </tr>
    <tr>
      <td>This risk exists in <font color="blue">clinical trials</font> as well as in     commercial  <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>We may incur <font color="blue">significant</font> expenses if product     <font color="blue">liability</font> lawsuits <font color="blue">against us</font> are successful</td>
    </tr>
    <tr>
      <td>Although we maintain product     <font color="blue">liability</font> insurance, our <font color="blue">coverage may</font> not be adequate to <font color="blue">cover such</font> claims</td>
    </tr>
    <tr>
      <td>Risks Related to Ownership of Our Stock          Our <font color="blue">stock price may</font> be volatile</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font> may fluctuate <font color="blue"><font color="blue">significant</font>ly</font> in response     to many <font color="blue">factors beyond</font> our control, including:           •   changes in the <font color="blue">recommendations</font> of <font color="blue">securities analysts</font> or changes in     their financial estimates of our operating results;           •   failures in meeting performance <font color="blue">expectations</font> of <font color="blue">securities analysts</font> or     investors;           •   <font color="blue">fluctuations</font> in the <font color="blue">valuations</font> of companies perceived <font color="blue">by securities</font>     analysts or investors to be comparable to us; and           •   share price and volume <font color="blue">fluctuations</font> attributable to <font color="blue">inconsistent</font>     <font color="blue">trading volume levels</font> of our shares</td>
    </tr>
    <tr>
      <td>Furthermore, the stock markets have experienced extreme price and volume     <font color="blue">fluctuations</font> that have affected and continue to affect the <font color="blue">market price</font>s of     equity securities of many companies</td>
    </tr>
    <tr>
      <td>In particular, there have been high     levels of <font color="blue">volatility</font> in the <font color="blue">market price</font>s of securities of bio<font color="blue">technology</font>     companies</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> often have <font color="blue">been unrelated</font> or <font color="blue">disproportionate</font>     to the operating performance of those companies</td>
    </tr>
    <tr>
      <td>These market and                                           35     ______________________________________________________________________    [62]Table of <font color="blue">Contents       </font>industry <font color="blue">fluctuations</font>, as well as general economic, political and market     <font color="blue">conditions</font>  such as recessions, interest rate changes or <font color="blue">international</font>     currency <font color="blue">fluctuations</font>, may negatively impact the <font color="blue">market price</font> of our common     stock</td>
    </tr>
    <tr>
      <td>In the past, companies that have experienced <font color="blue">volatility</font> in the market     price  of  their  stock  have  been subject to securities class action     <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>We may be the target of this type of <font color="blue">litigation</font> in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Securities </font><font color="blue">litigation</font> <font color="blue">against us</font> could result in substantial costs and     divert our <font color="blue">management</font>’s attention from other business concerns, <font color="blue">which could</font>     <font color="blue">seriously harm</font> our business</td>
    </tr>
    <tr>
      <td>Certain of our <font color="blue">shareholders</font> have <font color="blue">significant</font> control of our <font color="blue">management</font> and     affairs,  which  they  could exercise against other <font color="blue">shareholders</font>’ best     interests</td>
    </tr>
    <tr>
      <td>Novo  Nordisk,  together  with  Warburg  Pincus Equity Partners, LP,     <font color="blue">beneficially</font> owned an aggregate of approximately 44prca of our outstanding     <font color="blue">common stock</font> as of <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td><font color="blue">Representatives </font>of these <font color="blue">shareholders</font>     hold  four  out  of  nine  seats on our board of <font color="blue">directors</font> pursuant to     <font color="blue">contractual</font> <font color="blue">obligations</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">shareholders</font>, acting together, have the     ability to <font color="blue"><font color="blue">significant</font>ly</font> influence our <font color="blue">management</font> and affairs and matters     requiring <font color="blue">shareholder approval</font>, including the election of <font color="blue">directors</font> and     approval  of  <font color="blue">significant</font>  corporate  <font color="blue">transactions</font>,  such  as mergers,     <font color="blue">consolidations</font> or the sale of <font color="blue">substantially</font> all of our assets</td>
    </tr>
    <tr>
      <td>Consequently,     these  <font color="blue">shareholders</font>, acting together, may be able to cause a change in     control, as well as delay or prevent a change in control</td>
    </tr>
    <tr>
      <td>They may also     discourage a <font color="blue">potential acquirer from</font> making a <font color="blue">tender offer</font> or otherwise     attempting to effect a change in control, even if such a change in control     <font color="blue">would benefit</font> our other <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td><font color="blue">Provisions </font>in our charter <font color="blue">documents</font> could prevent or frustrate any attempts     to replace our <font color="blue">current board</font> of <font color="blue">directors</font> or <font color="blue">management</font> by <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>Our  articles  of <font color="blue">incorporation</font> and bylaws contain provisions, such as     <font color="blue">undesignated preferred stock</font> and <font color="blue">prohibitions</font> on cumulative voting in the     election of <font color="blue">directors</font>, <font color="blue">which could</font> make it more <font color="blue">difficult</font> for a <font color="blue">third party</font>     to acquire us without the consent of our board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Also, our     articles  of  <font color="blue">incorporation</font>  provide for a staggered board, removal of     <font color="blue">directors</font>  only for cause and certain <font color="blue">requirements</font> for <font color="blue">calling special</font>     <font color="blue">shareholder meetings</font></td>
    </tr>
    <tr>
      <td>In addition, our bylaws require advance notice of     <font color="blue">shareholder proposals</font> and <font color="blue">nominations</font> and impose <font color="blue">restrictions</font> on the persons     who may call special <font color="blue">shareholder meetings</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions may</font> have the     effect  of preventing or hindering any <font color="blue">attempts by</font> our <font color="blue">shareholders</font> to     replace our <font color="blue">current board</font> of <font color="blue">directors</font> or <font color="blue">management</font></td>
    </tr>
  </tbody>
</table>